Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
AFFF Lawsuit Exposure to firefighting foam chemicals may result in an increased risk of cancer for firefighters, military and airport personnel.
Paraquat Parkinson’s Disease Lawsuits Exposure to the toxic herbicide Paraquat has been linked to a risk of Parkinson's disease.
FDA Informs Doctors about Reports of Progressive Multifocal Leukoencephalopathy (PML) August 26, 2008 AboutLawsuits Add Your Comments The FDA has issued a notice to healthcare providers with information about two new reports of progressive multifocal leukoencephalopathy (PML), a rare brain disease, which have occurred among two patients in Europe who were receiving the multiple sclerosis drug Tysabri. Information about the two cases of this progressive and potentially fatal disease were first disclosed earlier this month in filings made by the drug manufacturers, Biogen Idec and Elan, with the Securities and Exchange Commission. Both users developed PML after taking Tysabri for at least 14 months, without simultaneous use of another multiple sclerosis drug. These new cases are important, since they are the first reports of the rare brain disease among Tysabri users since the drug was reintroduced two years ago. It was removed from the market in 2005 after two deaths from three cases of PML were associated with the drug. It was allowed to return in 2006 with stricter guidelines and more prominent warnings about progressive multifocal leukoencephalopathy as a potential side effect of the treatment. Do You Know about… hair dye cancer lawsuits For Salon Professionals Hair dye lawsuits are being pursued for salon professionals who were routinely exposed to hair dye chemicals and diagnosed with bladder cancer or breast cancer. See if you qualify for a hair dye cancer lawsuit settlement. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Do You Know About… hair dye cancer lawsuits For Salon Professionals Hair dye lawsuits are being pursued for salon professionals who were routinely exposed to hair dye chemicals and diagnosed with bladder cancer or breast cancer. See if you qualify for a hair dye cancer lawsuit settlement. Learn More SEE IF YOU QUALIFY FOR COMPENSATION The FDA posted the information Monday through their MedWatch Alert System, urging doctors to only prescribe Tysabri to patients who are enrolled in a special program, known as the TOUCH Prescribing Program. TOUCH is a risk minimization plan, where every patient is closely watched and monitored for PML and other adverse opportunistic infections. The program is also designed to assess the risk of PML, promote informed decisions among users and to minimize the number of disabilities and deaths due to progressive multifocal leukoencephalopathy. Tysabri was initially launched in 2004, as an intravenous injection given every 28 days to treat multiple sclerosis (MS). Earlier this year, the FDA approved an additional use for Tysabri to treat Chron’s disease, where patients have failed other treatments, such as Remicade and Humira. PML, also known as progressive multifocal leukoencephalitis, is characterized by progressive damage and inflammation at multiple locations in the brain, leading to permanent brain damage. Symptoms of PML include paralysis, weakness, impaired speech, and loss of vision. It is rare viral disease, which has no effective cure and can be fatal. The two new cases of PML in Europe were reported among patients with multiple sclerosis who received Tysabri as a monotherapy, and both used the drug for more than a year. Previous cases of PML associated with Tysabri had occurred only in multiple sclerosis patients who took other immunomodulatory drugs in combination with the medication. The FDA indicates that data suggests individuals who use Tysabri alone have a lower risk of developing PML than those who use it with other immunomodulatory medications. No new cases of PML associated with Tysabri have been reported in the United States. At least 7,500 people have used the drug for more than a year in the U.S. and about 3,300 patients received the drug for at least one and a half years. Approximately 39,000 patients worldwide have been treated with Tysabri, with 12,000 of them having undergone treatment for at least a year. The FDA and the manufacturer are reviewing changes to the product label to inform patients and prescribers that the use of Tysabri as a monotherapy has resulted in cases of progressive multifocal leukoencephalopathy. Tags: Progressive Multifocal Leukoencephalopathy (PML), Tysabri More Lawsuit Stories Depo-Provera Meningioma Diagnosis Information Required To Qualify for Lawsuit: Order April 1, 2025 Judge Rejects J&J’s Third Bankruptcy Filing, Killing $9B Talcum Powder Settlement April 1, 2025 Igloo Cooler Class Action Lawsuit Filed Over Fingertip Amputation Risks April 1, 2025 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermPhoneThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Depo-Provera Meningioma Diagnosis Information Required To Qualify for Lawsuit: Order (Posted: today) Women pursuing Depo-Provera meningioma lawsuits will have to provide documentary proof of their diagnosis and the versions of the birth control shot they received within 120 days of filing their case. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Lawsuit Timeline for Preparing Pilot Trial Cases Outlined by MDL Judge (03/24/2025)Women Can File Depo-Provera Brain Tumor Lawsuits Directly in MDL: Court Order (03/18/2025)75 Lawyers in Depo-Provera Lawsuits Seek MDL Leadership Roles (03/10/2025) Cartiva SCI Lawsuit Alleges Toe Implant Worsened Pain, Decreased Range of Motion (Posted: yesterday) An Indiana woman has filed a Cartiva SCI implant lawsuit, indicating that the toe implant failed due to a defective design, resulting in the need for revision surgery and recommendations to permanently fuse her big toe. MORE ABOUT: CARTIVA IMPLANT LAWSUITCartiva Implant Injury Lawsuit Set for Trial in February 2026 (03/07/2025)Lawsuit Indicates Cartiva Implant Fails in 2 Out of 3 Patients, But Continued To Be Sold in U.S. (02/13/2025)Cartiva Toe Implant Lawsuit Filed Over Worsened Pain, Reduced Range of Motion and Need for Surgical Removal (02/07/2025) Salon Professionals Claim Occupational Exposure to Hair Dye Products Caused Bladder Cancer: Lawsuits (Posted: 4 days ago) Two California hair stylists filed separate lawsuits, indicating that repeated occupational exposure to toxic chemicals in hair coloring dyes caused them to develop bladder cancer. MORE ABOUT: HAIR DYE LAWSUITHair Color Lawsuit Filed Over Salon Worker’s Bladder Cancer Diagnosis (03/20/2025)Brazilian Blowout Cancer Lawsuit Filed by Missouri Hair Stylists Over Exosure to Toxic Chemicals (03/11/2025)Initial Status Conference for Hair Dresser’s Bladder Cancer Lawsuit Set for May 5 (03/10/2025)
Depo-Provera Meningioma Diagnosis Information Required To Qualify for Lawsuit: Order (Posted: today) Women pursuing Depo-Provera meningioma lawsuits will have to provide documentary proof of their diagnosis and the versions of the birth control shot they received within 120 days of filing their case. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Lawsuit Timeline for Preparing Pilot Trial Cases Outlined by MDL Judge (03/24/2025)Women Can File Depo-Provera Brain Tumor Lawsuits Directly in MDL: Court Order (03/18/2025)75 Lawyers in Depo-Provera Lawsuits Seek MDL Leadership Roles (03/10/2025)
Cartiva SCI Lawsuit Alleges Toe Implant Worsened Pain, Decreased Range of Motion (Posted: yesterday) An Indiana woman has filed a Cartiva SCI implant lawsuit, indicating that the toe implant failed due to a defective design, resulting in the need for revision surgery and recommendations to permanently fuse her big toe. MORE ABOUT: CARTIVA IMPLANT LAWSUITCartiva Implant Injury Lawsuit Set for Trial in February 2026 (03/07/2025)Lawsuit Indicates Cartiva Implant Fails in 2 Out of 3 Patients, But Continued To Be Sold in U.S. (02/13/2025)Cartiva Toe Implant Lawsuit Filed Over Worsened Pain, Reduced Range of Motion and Need for Surgical Removal (02/07/2025)
Salon Professionals Claim Occupational Exposure to Hair Dye Products Caused Bladder Cancer: Lawsuits (Posted: 4 days ago) Two California hair stylists filed separate lawsuits, indicating that repeated occupational exposure to toxic chemicals in hair coloring dyes caused them to develop bladder cancer. MORE ABOUT: HAIR DYE LAWSUITHair Color Lawsuit Filed Over Salon Worker’s Bladder Cancer Diagnosis (03/20/2025)Brazilian Blowout Cancer Lawsuit Filed by Missouri Hair Stylists Over Exosure to Toxic Chemicals (03/11/2025)Initial Status Conference for Hair Dresser’s Bladder Cancer Lawsuit Set for May 5 (03/10/2025)